1 Centre for Infectious Disease, Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, UK 2 Division of Infection, Inflammation and Repair, University ...
Introduction Training procedural skills in GI endoscopy once focused on threshold numbers. As threshold numbers poorly reflect individual competence, the focus gradually shifts towards a more ...
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disorder worldwide, reflecting the growing prevalence of obesity and type 2 diabetes. Some patients ...
IBD has become a global disease in the 21st century that shifts through four epidemiological stages. Alterations in the gut ...
Zhou and colleagues published an observational study on the beneficial effects of statin use in steatotic liver disease.1 Using a large, multicentre database, the author reported that statin use in ...
Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea Correspondence to Professor Young-Suk Lim, Department of ...
Objective Our previous studies have identified CXCL8 as the crucial chemokine responsible for gastric cancer metastasis mediated by loss of RACK1. However, the regulatory effect of CXCL8 on immune ...
Background Globally, an estimated 296 million individuals live with chronic hepatitis B virus (HBV) infection, carrying ...
Correspondence to Marc G Besselink, Department of Surgery, Amsterdam Gastroenterology and Metabolism, AMC Amsterdam, 22660, Amsterdam, The Netherlands; m.g.besselink{at}amc.uva.nl Acute pancreatitis ...
Objectives Gastro-oesophageal reflux symptoms are common in the community, but there has been no definitive systematic review and meta-analysis of data from all studies to estimate their global ...
Background Autoimmune hepatitis (AIH) is characterised by death of hepatocytes and chronic inflammation. Patients with deleterious variants in A20 are identified with AIH presentations and immune ...
Background In the hepatitis B e antigen positive (HBeAg+) chronic infection disease phase, approved treatments have limited effects on hepatitis B surface antigen (HBsAg) and HBeAg. Objective The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback